244 related articles for article (PubMed ID: 27694325)
1. Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro-Fibrotic Signaling.
Haller ST; Yan Y; Drummond CA; Xie J; Tian J; Kennedy DJ; Shilova VY; Xie Z; Liu J; Cooper CJ; Malhotra D; Shapiro JI; Fedorova OV; Bagrov AY
J Am Heart Assoc; 2016 Sep; 5(10):. PubMed ID: 27694325
[TBL] [Abstract][Full Text] [Related]
2. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy.
Elkareh J; Kennedy DJ; Yashaswi B; Vetteth S; Shidyak A; Kim EG; Smaili S; Periyasamy SM; Hariri IM; Fedorova L; Liu J; Wu L; Kahaleh MB; Xie Z; Malhotra D; Fedorova OV; Kashkin VA; Bagrov AY; Shapiro JI
Hypertension; 2007 Jan; 49(1):215-24. PubMed ID: 17145984
[TBL] [Abstract][Full Text] [Related]
3. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy.
Kennedy DJ; Vetteth S; Periyasamy SM; Kanj M; Fedorova L; Khouri S; Kahaleh MB; Xie Z; Malhotra D; Kolodkin NI; Lakatta EG; Fedorova OV; Bagrov AY; Shapiro JI
Hypertension; 2006 Mar; 47(3):488-95. PubMed ID: 16446397
[TBL] [Abstract][Full Text] [Related]
4. Na/K-ATPase signaling regulates collagen synthesis through microRNA-29b-3p in cardiac fibroblasts.
Drummond CA; Hill MC; Shi H; Fan X; Xie JX; Haller ST; Kennedy DJ; Liu J; Garrett MR; Xie Z; Cooper CJ; Shapiro JI; Tian J
Physiol Genomics; 2016 Mar; 48(3):220-9. PubMed ID: 26702050
[TBL] [Abstract][Full Text] [Related]
5. Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy.
Elkareh J; Periyasamy SM; Shidyak A; Vetteth S; Schroeder J; Raju V; Hariri IM; El-Okdi N; Gupta S; Fedorova L; Liu J; Fedorova OV; Kahaleh MB; Xie Z; Malhotra D; Watson DK; Bagrov AY; Shapiro JI
Am J Physiol Renal Physiol; 2009 May; 296(5):F1219-26. PubMed ID: 19261738
[TBL] [Abstract][Full Text] [Related]
6. Reduction of Na/K-ATPase potentiates marinobufagenin-induced cardiac dysfunction and myocyte apoptosis.
Liu C; Bai Y; Chen Y; Wang Y; Sottejeau Y; Liu L; Li X; Lingrel JB; Malhotra D; Cooper CJ; Shapiro JI; Xie ZJ; Tian J
J Biol Chem; 2012 May; 287(20):16390-8. PubMed ID: 22451662
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure.
Haller ST; Kennedy DJ; Shidyak A; Budny GV; Malhotra D; Fedorova OV; Shapiro JI; Bagrov AY
Am J Hypertens; 2012 Jun; 25(6):690-6. PubMed ID: 22378033
[TBL] [Abstract][Full Text] [Related]
8. Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.
Tian J; Shidyak A; Periyasamy SM; Haller S; Taleb M; El-Okdi N; Elkareh J; Gupta S; Gohara S; Fedorova OV; Cooper CJ; Xie Z; Malhotra D; Bagrov AY; Shapiro JI
Hypertension; 2009 Dec; 54(6):1313-20. PubMed ID: 19884563
[TBL] [Abstract][Full Text] [Related]
9. Dietary Sodium Restriction Reduces Arterial Stiffness, Vascular TGF-β-Dependent Fibrosis and Marinobufagenin in Young Normotensive Rats.
Grigorova YN; Wei W; Petrashevskaya N; Zernetkina V; Juhasz O; Fenner R; Gilbert C; Lakatta EG; Shapiro JI; Bagrov AY; Fedorova OV
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326586
[TBL] [Abstract][Full Text] [Related]
10. Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension.
Fedorova OV; Talan MI; Agalakova NI; Droy-Lefaix MT; Lakatta EG; Bagrov AY
Hypertension; 2003 Mar; 41(3):505-11. PubMed ID: 12623951
[TBL] [Abstract][Full Text] [Related]
11. Antibody against Na/K-ATPase Inhibitor Lowers Blood Pressure and Increases Vascular Fli1 in Experimental Preeclampsia.
Agalakova NI; Reznik VA; Nadei OV; Ershov IA; Rassokha OS; Vasyutina ML; Ivanov DO; Adair CD; Galagudza MM; Bagrov AY
Am J Hypertens; 2020 May; 33(6):514-519. PubMed ID: 31713584
[TBL] [Abstract][Full Text] [Related]
12. Passive immunization against marinobufagenin attenuates renal fibrosis and improves renal function in experimental renal disease.
Haller ST; Drummond CA; Yan Y; Liu J; Tian J; Malhotra D; Shapiro JI
Am J Hypertens; 2014 Apr; 27(4):603-9. PubMed ID: 24014658
[TBL] [Abstract][Full Text] [Related]
13. Endogenous cardiotonic steroids in chronic renal failure.
Kolmakova EV; Haller ST; Kennedy DJ; Isachkina AN; Budny GV; Frolova EV; Piecha G; Nikitina ER; Malhotra D; Fedorova OV; Shapiro JI; Bagrov AY
Nephrol Dial Transplant; 2011 Sep; 26(9):2912-9. PubMed ID: 21292813
[TBL] [Abstract][Full Text] [Related]
14. Marinobufagenin, an endogenous alpha-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats.
Fedorova OV; Kolodkin NI; Agalakova NI; Lakatta EG; Bagrov AY
Hypertension; 2001 Feb; 37(2 Pt 2):462-6. PubMed ID: 11230319
[TBL] [Abstract][Full Text] [Related]
15. The cardiotonic steroid hormone marinobufagenin induces renal fibrosis: implication of epithelial-to-mesenchymal transition.
Fedorova LV; Raju V; El-Okdi N; Shidyak A; Kennedy DJ; Vetteth S; Giovannucci DR; Bagrov AY; Fedorova OV; Shapiro JI; Malhotra D
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F922-34. PubMed ID: 19176701
[TBL] [Abstract][Full Text] [Related]
16. Antibody to Marinobufagenin Reverses Placenta-Induced Fibrosis of Umbilical Arteries in Preeclampsia.
Fedorova OV; Ishkaraeva VV; Grigorova YN; Reznik VA; Kolodkin NI; Zazerskaya IE; Zernetkina V; Agalakova NI; Tapilskaya NI; Adair CD; Lakatta EG; Bagrov AY
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30104471
[TBL] [Abstract][Full Text] [Related]
17. Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism.
Bagrov AY; Dmitrieva RI; Dorofeeva NA; Fedorova OV; Lopatin DA; Lakatta EG; Droy-Lefaix MT
J Hypertens; 2000 Feb; 18(2):209-15. PubMed ID: 10694190
[TBL] [Abstract][Full Text] [Related]
18. Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists.
Fedorova OV; Emelianov IV; Bagrov KA; Grigorova YN; Wei W; Juhasz O; Frolova EV; Marshall CA; Lakatta EG; Konradi AO; Bagrov AY
J Hypertens; 2015 Aug; 33(8):1602-10. PubMed ID: 26136067
[TBL] [Abstract][Full Text] [Related]
19. Effect of Cardiotonic Steroid Marinobufagenin on Vascular Remodeling and Cognitive Impairment in Young Dahl-S Rats.
Grigorova YN; Juhasz O; Long JM; Zernetkina VI; Hall ML; Wei W; Morrell CH; Petrashevskaya N; Morrow A; LaNasa KH; Bagrov AY; Rapp PR; Lakatta EG; Fedorova OV
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562955
[TBL] [Abstract][Full Text] [Related]
20. Cardiotonic Steroids Induce Vascular Fibrosis Via Pressure-Independent Mechanism in NaCl-Loaded Diabetic Rats.
Fedorova OV; Fadeev AV; Grigorova YN; Marshall CA; Zernetkina V; Kolodkin NI; Agalakova NI; Konradi AO; Lakatta EG; Bagrov AY
J Cardiovasc Pharmacol; 2019 Nov; 74(5):436-442. PubMed ID: 31415452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
